MARCO Inhibitors
The protein MARCO, short for Macrophage Receptor with Collagenous Structure, is primarily expressed in macrophages, where it plays a crucial role in innate immunity and host defense mechanisms. MARCO functions as a pattern recognition receptor (PRR) involved in the recognition and clearance of various pathogens, including bacteria, viruses, and fungi, as well as foreign particles and apoptotic cells. Its extracellular domain contains collagenous regions that interact with a diverse array of ligands, facilitating the phagocytosis of microbial pathogens and cellular debris by macrophages. By recognizing and binding to these ligands, MARCO initiates signaling cascades that trigger the engulfment and degradation of the captured particles, thus contributing to the resolution of infections and maintenance of tissue homeostasis.
Inhibition of MARCO activity can occur through various mechanisms, resulting in impaired phagocytosis and immune responses. One common mechanism involves blocking the ligand-binding sites on the extracellular domain of MARCO, preventing its interaction with pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). This interference with ligand recognition and binding inhibits the downstream signaling events required for phagocytosis initiation, thereby reducing the ability of macrophages to clear pathogens and debris from the host. Additionally, inhibition of MARCO expression or function may occur at the transcriptional or post-translational level through regulatory pathways that modulate its activity. Such mechanisms could involve the downregulation of MARCO gene expression or the disruption of its intracellular trafficking and localization, leading to decreased cell surface expression and impaired phagocytic activity. Overall, inhibition of MARCO represents a strategy for modulating immune responses and controlling inflammation, although further research is needed to elucidate the specific pathways and molecules involved in regulating its function.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a kinase inhibitor that primarily targets RAF/MEK/ERK signaling pathway. By inhibiting RAF kinases, it disrupts the MAPK pathway, indirectly influencing MARCO. Sorafenib’s action on downstream effectors results in altered cellular responses, impacting the regulation of MARCO expression and function within the cell. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. By specifically targeting this key component of the MAPK signaling pathway, it modulates downstream events that influence MARCO expression. The inhibition of p38 MAP kinase disrupts the cellular processes that normally regulate MARCO, providing a means to indirectly control MARCO activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). Through its action on PI3K, it affects the PI3K/Akt signaling pathway. This modulation indirectly influences MARCO by altering the cellular processes regulated by PI3K, subsequently impacting the expression and function of MARCO within the cell. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits the mammalian target of rapamycin (mTOR) pathway. By doing so, it disrupts the downstream signaling events that are crucial for regulating MARCO expression and function. The inhibition of mTOR alters the cellular environment, indirectly influencing MARCO and its involvement in cellular processes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor. Through inhibition of PI3K, it influences the PI3K/Akt signaling pathway, indirectly impacting MARCO expression. The disruption of this pathway alters cellular processes that contribute to the regulation of MARCO, providing an indirect means to modulate MARCO activity within the cell. | ||||||
Tozasertib | 639089-54-6 | sc-358750 sc-358750A | 25 mg 50 mg | $62.00 $87.00 | 4 | |
VX-680, also known as Tozasertib, is an Aurora kinase inhibitor. Its action on Aurora kinases affects the regulation of cell division. By disrupting this process, VX-680 indirectly influences MARCO expression, as cell division plays a role in MARCO-related cellular functions. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a selective inhibitor of c-Jun N-terminal kinase (JNK). Through inhibition of JNK, it impacts the JNK signaling pathway, indirectly influencing MARCO expression. The disruption of this pathway alters cellular processes that contribute to the regulation of MARCO, providing an indirect means to modulate MARCO activity within the cell. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
Bay 11-7082 inhibits the nuclear factor-kappa B (NF-κB) pathway. By targeting NF-κB, it modulates downstream events that indirectly influence MARCO expression. The inhibition of NF-κB disrupts the cellular processes that normally regulate MARCO, providing an indirect means to control MARCO activity within the cell. | ||||||
JNK Inhibitor XVI | 1410880-22-6 | sc-364745 | 10 mg | $357.00 | 5 | |
JNK Inhibitor XVI is a potent JNK inhibitor. Its action on JNK influences the JNK signaling pathway, indirectly affecting MARCO expression. The disruption of this pathway alters cellular processes that contribute to the regulation of MARCO, providing an indirect means to modulate MARCO activity within the cell. | ||||||
PF-562271 | 717907-75-0 | sc-478488 sc-478488A sc-478488B | 5 mg 10 mg 50 mg | $312.00 $474.00 $1124.00 | 3 | |
PF-562271 is a focal adhesion kinase (FAK) inhibitor. Its action on FAK disrupts the FAK signaling pathway, indirectly influencing MARCO expression. The inhibition of FAK alters cellular processes that contribute to the regulation of MARCO, providing an indirect means to modulate MARCO activity within the cell. | ||||||